Gynecologic Cancer SurvivorsNCT07910162
Developing a Gynecologic Cancer Health Promotion Community Engagement Program
An observational study of Gynecologic Cancer Survivors, run by Abramson Cancer Center at Penn Medicine at 1 site in United States.
Trial summary
The goal of this observational study is to learn about the communication systems of gynecologic cancer survivors by conducting focus groups and disseminating a survey. Gynecologic cancer survivors at Penn Medicine who have consented to being contacted for participation in research will be asked to join the study. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Gynecologic Cancer Survivors
- How many people
- 100 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Jun 2026to 1 Jun 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Study population: Gynecologic cancer survivors at Penn Medicine who have consented to being contacted for participation in research
Who may be able to join
- Gynecologic cancer survivors at Penn Medicine who have consented to being contacted for participation in research.
- Age > 18 years old.
- Diagnosis of cancer at least 6 months prior to recruitment date.
Who cannot join
- Age < 18 years old.
- Patients unable to provide consent due to mental incapacity or lack of cognitive ability to understand the information provided.
- Diagnosis date within 6 months of recruitment date.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
University of Pennsylvania
Philadelphia, Pennsylvania, 19140
About this study
The goal of this observational study is to learn about the communication systems of gynecologic cancer survivors by conducting focus groups and disseminating a survey.
Gynecologic cancer survivors at Penn Medicine who have consented to being contacted for participation in research will be asked to join the study.
Read the detailed description
First, a mixed-methods study of gynecologic cancer survivors will be conducted to assess perceptions, barriers, and facilitators to discussing gynecologic cancers through the family and community and create a toolkit for communication.
Separately, a network-map will be created to integrate social-community-advocacy-provider map to disseminate information and facilitate community-based participatory research in gynecologic cancers, by leveraging extensive collaborative teams locally and nationally.
- Conditions
- Gynecologic Cancer Survivors
- Keywords
- ovarian cancer survivor, endometrial cancer survivor, cervical cancer survivor
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Ovarian cancer surivors | Patients who have been diagnosed with ovarian cancer and have received at least 1 prior line of therapy. | |
| Endometrial cancer survivors | Patients who have been diagnosed with endometrial cancer and have received at least 1 prior line of therapy. | |
| Cervical cancer survivors | Patients who have been diagnosed with cervical cancer and have received at least 1 prior line of therapy. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Themes Identified from Focus Groups and Surveys
Thematic analysis of transcripts from semi-structured interviews to identify primary thematic categories regarding barriers and facilitators to discussing gynecologic cancer. Count/listing of identified primary qualitative themes will be performed.
Measured: From enrollment to June 2027.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Nov 2026
- Study start1 Jun 2026
- Primary completion1 Jun 2027 (estimated)
- Study completion1 Jun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gynecologic Cancer SurvivorsStudies of the same condition, open and under way.
- More trials run by Abramson Cancer Center at Penn MedicineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Emily Ko, MD, Abramson Cancer Center at Penn Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07910162
- Sponsor's protocol ID
- UPCC 40825
- Other IDs
- IRB 859743
- Status last verified
- Oct 2026
- First submitted
- 17 Sep 2026
- Last updated
- 2 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Only IPD used in the results publication
Study at a glance
From the registry record, last updated by the sponsor on 2 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Developing a Gynecologic Cancer Health Promotion Community Engagement Program
- ClinicalTrials.gov ID
- NCT07910162
- Acronym / sponsor ID
- UPCC 40825
- Conditions
- Gynecologic Cancer Survivors
- Keywords
- ovarian cancer survivor, endometrial cancer survivor, cervical cancer survivor
- Study type
- Observational
- Recruitment status
- Enrolling by invitation
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Abramson Cancer Center at Penn MedicineUniversity, hospital or other
- Study start
- 1 Jun 2026 (actual)
- Primary completion
- 1 Jun 2027 (estimated)
- Study completion
- 1 Jun 2028 (estimated)
- First posted
- 2 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to learn about the communication systems of gynecologic cancer survivors by conducting focus groups and disseminating a survey.
Gynecologic cancer survivors at Penn Medicine who have consented to being contacted for participation in research will be asked to join the study.
Detailed description
First, a mixed-methods study of gynecologic cancer survivors will be conducted to assess perceptions, barriers, and facilitators to discussing gynecologic cancers through the family and community and create a toolkit for communication.
Separately, a network-map will be created to integrate social-community-advocacy-provider map to disseminate information and facilitate community-based participatory research in gynecologic cancers, by leveraging extensive collaborative teams locally and nationally.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Ovarian cancer surivors | – | –Patients who have been diagnosed with ovarian cancer and have received at least 1 prior line of therapy. |
| Endometrial cancer survivors | – | –Patients who have been diagnosed with endometrial cancer and have received at least 1 prior line of therapy. |
| Cervical cancer survivors | – | –Patients who have been diagnosed with cervical cancer and have received at least 1 prior line of therapy. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Gynecologic cancer survivors at Penn Medicine who have consented to being contacted for participation in research
Key inclusion criteria (3 listed)
- Gynecologic cancer survivors at Penn Medicine who have consented to being contacted for participation in research.
- Age > 18 years old.
- Diagnosis of cancer at least 6 months prior to recruitment date.
Key exclusion criteria (3 listed)
- Age < 18 years old.
- Patients unable to provide consent due to mental incapacity or lack of cognitive ability to understand the information provided.
- Diagnosis date within 6 months of recruitment date.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Themes Identified from Focus Groups and Surveys
Time frame: From enrollment to June 2027.
Thematic analysis of transcripts from semi-structured interviews to identify primary thematic categories regarding barriers and facilitators to discussing gynecologic cancer. Count/listing of identified primary qualitative themes will be performed.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Nov 2026.
- Individual participant dataSharing planned: Yes. Only IPD used in the results publication
Related trials for Gynecologic Cancer Survivors
RecruitingObservational study
Assessment of Sexual Well-being in Patients With Gynecologic Cancer and Their Partners: the ONCOSEX Study
Sexual Wellness, Gynecologic Cancers
Recruiting
An Individualized Online Home-Based Exercise Program for Improving Symptoms in Gynecologic Cancer Survivors
Malignant Female Reproductive System Neoplasm
Active, not recruitingPhase 1
Virtual Mindful After Cancer (MAC) Intervention to Promote Sexual Health for Breast and Gynecologic Cancer Survivors
Gynecologic Cancers, Breast Cancer
Active, not recruitingObservational study
Follow-up in Gynecological Cancer Survivors
Gynecologic Cancer
Recruiting
Intelligent Sexual Health Information Support System for Gynecological Cancer Patients
Sexual and Reproductive Health, Gynecologic Cancer Survivors
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Gynecologic Cancer Survivors, run by Abramson Cancer Center at Penn Medicine at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 2 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Themes Identified from Focus Groups and Surveys (time frame: From enrollment to June 2027.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Nov 2026.